All In Biotech

Drug Trial Radar · NCT06577090

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

A Phase 2 Study of QW Nimacimab Injection, Compared to Placebo Injection and QW Weekly Nimacimab Injection Co-administered With Semaglutide in Participants Who Are Overweight or Obese

Last checked: Nov 19, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

136

Actual

Start

Aug 22, 2024

Primary completion

Nov 20, 2026

Study completion Feb 28, 2027

Sponsor

Lead sponsor
Skye Bioscience, Inc.Industry
Sponsor type
Industry
First posted
Aug 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.

Conditions

  • Obesity

Interventions

  • Nimacimab injectionBiological

    Nimacimab injection 200 mg

  • Nimacimab placebo injectionBiological

    matching nimacimab placebo injection

  • semaglutide injectionCombination product

    semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg + nimacimab 200 mg

  • Nimacimab 300 mg injectionBiological

    Nimacimab injection 300 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in body weight (main study)Time frame: From Baseline to Week 26
  2. Nature, frequency and severity of AEs (study extension)Time frame: Baseline through Week 38 of study extension (approximately 10 months of participation)

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Pinnacle Research Group

    Anniston, Alabama

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Chase Medical Research, LLC

    Waterbury, Connecticut

  • ACCEL Research Sites

    Atlanta, Georgia

  • Center for Advanced Research & Education

    Gainesville, Georgia

  • L-MARC Research Center

    Louisville, Kentucky

  • Be Well Clinical Studies

    Lincoln, Nebraska

  • Palm Research Center

    Las Vegas, Nevada

  • ActivMed Practices & Research

    Portsmouth, New Hampshire

  • Weill Cornell Medicine

    New York, New York

  • Accellacare of Wilmington

    Wilmington, North Carolina

  • Lillestol Research, LLC

    Fargo, North Dakota

  • Velocity Clinical Research, Dallas

    Dallas, Texas

  • Be Well Clinical Studies

    Round Rock, Texas

  • Charlottesville Medical Research

    Charlottesville, Virginia

  • Rainier Clinical Research Center

    Renton, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.